Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial

Journal of the American Medical Association

Volumn 276, Issue 24, 1996, Pages 1957-1963

  Clark, Larry C ^a   Combs Jr , Gerald F ^b   Turnbull, Bruce W ^b   Slate, Elizabeth H ^b   Chalker, Dan K ^b   Chow, James ^b   Davis, Loretta S ^b   Glover, Renee A ^b   Graham, Gloria F ^b   Gross, Earl G ^b   Krongrad, Arnon ^b   Lesher Jr , Jack L ^b   Park, H Kim ^b   Sanders Jr , Beverly B ^b   Smith, Cameron L ^b   Taylor, J Richard ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

SELENIUM;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

EID: 1642625262     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.24.1957     Document Type: Article

References (58)

1. Shamberger RJ, Frost DV. Possible protective effect of selenium against human cancer. Can Med Assoc J. 1969;100:682.
2. Shamberger RJ, Willis CE. Seienium distribution of human cancer mortality. Crit. Rev Clin Lab Sci. 1971;2:211-221.
3. Schrauzer GN, Thead WJ. Interpretation of the methylene blue reduction test of human plasma and the possible cancer proteeting effect of selenium. Experientia. 1971;7:1069-1071.
4. Combs GF Jr, Combs S. The Role of Selenium in Nutrition. New York, NY: Academic Press; 1986.
5. Burk RF, Hill KE. Regulation of selenoproteins. Annu Rev Nutr. 1993;13:65-81.
6. Combs GF Jr. Essentiality and toxicity of selenium: a critique of the recommended dietary allowance and the reference dose. In: Mertz W, Abernathy CO, Olin SS, eds. Risk Assessment of Essential Elements. Washington, DC: ILSI Press; 1994:167-183.
7. Subcommittee on the Tenth Edition of the RDAs, Food and Nutrition Board, Commission on Life Sciences, National Research Council. Recommended Dietary Allowances, Tenth Edition. Washington, DC: National Academy Press; 1989.
8. Combs GF Jr. Selenium and cancer. In: Wang Z, ed. Biochemistry and Molecular Biology of Selenium. Beijing, China: Chinese Academy of Science; 1995.
9. Milner JA. Effect of selenium on virally induced and transplantable tumor models. Fed Proc. 1985; 44:2568-2572.
10. Ip C. The chemopreventive role of selenium in earcinogenesis. J Am Coll Toxicol. 1986;5:7-20
11. Ip C, Medina D. Current concept of selenium and mammary tumorigenesis. In: Medina D, Kidwell W, Heppner G, Anderson EP, eds. Cellular and Molecular Biology of Breast Cancer. New York, NY: Plenum Press; 1987:479.
12. El-Bayoumy K. The role of selenium in cancer prevention. In: DeVita VT, Hellman S, Rosenberg SS, eds. Practice of Oncology. 4th ed. Philadelphia, Pa: JB Lippincott; 1991:1-15.
13. Schrauzer GN, White DA, Schneider CJ. Cancer mortality correlation studies, III. Bioinorganic Chem. 1977;723-34.
14. Clark LC, Cantor KP, Allaway WH. Selenium in forage crops and cancer mortality in US counties. Arch Environ Health. 1991;46:37-42.
15. Clark LC. The epidemiology of selenium and cancer. Fed Proc. 1985;44:2584-2590.
16. Salonen JT, Alfthan G, Huttunen JK, Puska P. Association between serum selenium and the risk of cancer. Am J Epidemiol 1984;120:342-349.
17. Salonen JT, Salonen R, Lappetelainen R, Mäenpää PH, Alfthan G, Puska P. Risk of cancer in relation to serum concentrations of selenium and vitamins A and E. BMJ. 1985;290:417-20.
18. Willett W, Polk B, Morris S, et al. Prediagnostic serum selenium and risk of cancer. Lancet. 1983;2: 130-134.
19. Kok FJ, De Bruijn AM, Hoftnan A, Vermeeren R, Valkenburg HA. Is serum selenium a risk fector for cancer in men only? Am J Epidemiol. 1987;125:12-16.
20. Virtamo J, Valkeila E, Alfthan G, Punsar S, Huttunen JK, Karvonen MJ. Serum selenium and risk of cancer. Cancer. 1987;60:145-148.
21. van den Brandt P, Goldbohm R, van't Veer P, et al. A prospective cohort study of toenail selenium levels and risk of gastrointestinal cancer. J Natl Cancer Inst. 1993;85:224-229.
22. Peleg I, Morris S, Hames CG. Is serum selenium a risk factor for cancer? Med Oncol Tumor Pharmacother. 1985;2:157-163.
23. Knekt P, Aromaa A, Maatela J, et al. Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst. 1990;82:864-868.
24. Glattre E, Thomassen Y, Thoresen SO, et al. Prediagnostic serum selenium in a case-control study of thyroid cancer. Int J Epidemiol. 1989;18:45-49.
25. Fex G, Pettersson B, Akesson B. Low plasma selenium as a risk factor for cancer death in middleaged men. Nutr Cancer. 1987;10221-229.
26. Menkes MS, Comstock GW, Vuilleumier JP, Helsing KJ, Rider AA, Brookmeyer RP. Serum betacarotene, vitamins A and E, selenium, and the risk of lung cancer. N Engl J Med. 1986;315:1250-1254.
27. Garland M, Morris JS, Stampfer MJ, et al. Prospective study of toenail selenium and cancer among women. J Natl Cancer Inst. 1995;87:497-505.
28. Schober SE, Comstock GW, Helsing KJ, et al. Serologic precursors of cancer. Am J Epidemiol. 1987;126:1033-1041.
29. Nomura A, Heilbrun LK, Morris JS, Stemmermann GN. Serum selenium and the risk of cancer, by specific sites. J Natl Cancer Inst. 1987;79:103-108.
30. Knekt P, Aromaa A, Maatela J, et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. Int J Cancer. 1988;42:846-850.
31. Ringstad J, Jacobsen BK, Tretli S, Thomassen Y. Serum selenium concentration associated with risk of cancer. J Clin Pathol. 1988;41:454-457.
32. Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF. Serum levels of selenium and retinol and the subsequent risk of cancer. Am J Epidemiol. 1988; 128:515-523.
33. Clark LC, Graham GF, Crouse RG, Crimson R, Hulka B, Shy CM. Plasma selenium and skin neoplasms. Nutr Cancer. 1984;6:13-21.
34. Clark LC, Graham GF, Turnbull BW, Bray J, Hulka B, Shy CM. Non-melanoma skin cancer and plasma selenium: a prospective cohort study. In: Combs GF Jr, Spallholz JE, Levander OA, Oldfield JE, eds, The Third International Symposium on Selenium in Biology and Medicine. Westport, Conn: AVI Publishing Co; 1986:1122-1135.
35. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China. J Natl Cancer Inst. 1993;85:1483-1492.
36. Li JY, Taylor PR, Li B. Nutrition intervention trials in Linxian, China. J Natl Cancer Inst. 1993; 85:1492-1498.
37. Olson OE, Palmer IS, Cary EE. Modification of the official fluorometric method for selenium in plants. J Assoc Off Anal Chem. 1975;58:117-126.
38. McShane LM, Clark LC, Combs GF Jr, Turnbull BW. Reporting the accuracy of biochemical measurements for epidemiologic and nutrition studies. Am J Clin Nutr. 1991;53:1354-1360.
39. Abu-Libdeh H, Turnbull BW, Clark LC. Analysis of multi-type recurrent events in longitudinal studies. Biometrics. 1990;46:1017-1023.
40. Luo X, Turnbull BW, Cai H, Clark LC. Regression for censored survival data with lag effects. Commun Stat. 1994;23:3417-3438.
41. Allaway WH, Kubota J, Losee F, Roth M. Selenium, molybdenum and vanadium in human blood. Arch Environ Health. 1968;16:342-348.
42. National Cancer Institute, State Cancer Control and Data Program. Cancer Mortality by Pentad 1953-1957 to 1983-1987. Bethesda, Md: National Institutes of Health; 1992.
43. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett. 1994;85:23-29.
44. Gailani MR, Leffell DJ, Ziegler A, Gross EG, Brash DE, Bale AE. Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma J Natl Cancer Inst. 1996;88:349-354.
45. Lanfear J, Fleming J, Wu L, Webster G, Harrison PR. The selenium metabolite selenodiglutathione induces po53 and apoptosis. Carcinogenesis. 1994; 15:1378-1392.
46. Yang GQ, Yin S, Zhou R. Studies of safe maximal daily dietary Se-intake in a seleniferous area of China. J Trace Elem Electrolytes Health Dis. 1989;3:123-130.
47. Thompson JH, Wilson A, Lu J, et al. Comparison of the effects of an organic and inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis. 1994;15:183-186.
48. Pahor M, Gurainik JM, Ferrucci L, et al. Calciumchannel blockade and incidence of cancer in aged populations. Lancet. 1996;348:493-497.
49. The LRC Study Group. The Lipid Research Clinics Coronary Primary Prevention Trial results. JAMA 1984;251:351-364.
50. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
51. Comstock GW, Bush TL, Helzlsouer K. Serum retinol, beta-carotene, vitamin E and selenium as related to subsequent cancer of specific sites. Am J Epidemiol. 1992;135:115-121.
52. Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics. 1987;43:487-498.
53. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
54. Tannock IF. False-positive results in clinical trials. J Natl Cancer Inst. 1996;88:206-207.
55. Cook RJ, Farewell VT. Multiplicity considerations in the design and analysis of clinical trials. J R Stat Soc A. 1996;159:93-110.
56. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, I: introduction and design. Br J Cancer. 1976;34:585-612.
57. Cox DR. In Discussion: Jennison C, Turnbull BW. Interim analyses. J R Stat Soc B. 1989;51:338.
58. Jennison C, Turnbull BW. Interim analyses. J R Stat Soc B. 1989;51:305-361.